Affimed (NASDAQ:AFMD) Given Market Perform Rating at Leerink Partners

Affimed (NASDAQ:AFMD)‘s stock had its “market perform” rating reissued by research analysts at Leerink Partners in a research note issued to investors on Tuesday, MarketBeat.com reports. They currently have a $0.39 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $5.00. Leerink Partners’ price target would suggest a potential upside of 200.00% from the stock’s current price.

Separately, StockNews.com started coverage on Affimed in a research report on Sunday. They set a “sell” rating on the stock. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $7.90.

Affimed Trading Down 3.0%

AFMD opened at $0.13 on Tuesday. Affimed has a 12 month low of $0.10 and a 12 month high of $8.95. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13. The business’s 50-day moving average price is $0.76 and its 200-day moving average price is $1.46.

Institutional Investors Weigh In On Affimed

A number of large investors have recently added to or reduced their stakes in AFMD. Northern Trust Corp bought a new stake in Affimed in the fourth quarter valued at $218,000. Intellectus Partners LLC lifted its position in shares of Affimed by 34.0% in the 4th quarter. Intellectus Partners LLC now owns 126,414 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 32,053 shares during the period. Finally, Jane Street Group LLC bought a new stake in shares of Affimed during the 3rd quarter valued at about $44,000. Institutional investors own 30.82% of the company’s stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.